Question 1

Is Canada or Latin America faster for a first-in-human device trial?

Accepted Answer

Latin America is typically faster to first patient. Canada's ITA carries a 30-day review target, but real-world activation varies by study (we confirm it per protocol) after ethics, contracting, and site readiness. In Latin America, ethics approval runs 4–8 weeks and first-patient timing varies by study (we confirm it per protocol) through the bioaccess® FIH-12™ model.

Question 2

Is Canada or Latin America cheaper?

Accepted Answer

Budget depends on study design; we provide a study-specific quote. Canada's genuine cost advantage is zero CTA review fees — but review fees are a rounding error against per-patient and site costs.

Question 3

Does bioaccess® run trials in Canada?

Accepted Answer

Yes, on demand. We activate the right investigators, sites and regulatory resources on demand, anywhere in the Americas, from Canada to Argentina. For a Canadian study, we bring in the investigators, sites and Health Canada regulatory support the protocol needs when the program starts. This comparison exists because the geography decision is the question sponsors actually ask, and we answer it honestly, including when the answer is Canada.

Canada vs Latin America for First-in-Human Device Trials